The advisory panel decided that clinical studies presented by Transkaryotic did not provide strong evidence that the drug worked.

FORBES: Magazine Article

Unfortunately, past evidence does not provide a strong case for optimism.

FORBES: It's Wednesday, November 7th: Now What?